6 results about "Treatment refractory" patented technology

The present application discloses a composition for the treatment of painful disc damage syndrome (PDDS), disc bulging, disc herniation, and disc protrusion, as well as an administration method and a recommended treatment protocol for administering an effective dose of the composition to a patient. The composition has anti-inflammatory, antioxidant, vasodilatory, and antispasmodic properties. The compound is administered intravenously over a specific period for pain relief.

To provide effective therapeutic agents for the treatment of refractory lymphatic and vascular diseases. Provided is a therapeutic agent for the treatment of refractory lymphatic and vascular diseases which contains sirolimus as an active ingredient. The administration of the therapeutic agent is initiated by oral or tube administration at a dosage determined according to parameters related to the pharmacokinetics of sirolimus in a patient having the disease and the weight and age of the patient.

To provide an effective, long-term and safe pharmaceutical composition for use in a method of treating treatment-refractory or treatment-resistant depression in a patient diagnosed as having the depression.SOLUTION: A pharmaceutical composition for use in a method of treating treatment-resistant depression in a patient, wherein the pharmaceutical composition comprises esketamine and wherein the patient has not responded to at least two oral antidepressants in a current depressive episode, the pharmaceutical composition comprising: The method provides a pharmaceutical composition comprising: administering esketamine to the patient at least twice a week during a first induction phase of at least 4 weeks; evaluating the patient during the first induction phase; wherein the patient does not achieve a substantially complete response to esketamine; and re-starting the patient with the highest tolerated dose of esketamine in a second induction phase of at least 4 weeks.SELECTED DRAWING: None

The present application discloses a composition for treating painful disc injury syndrome (PDDS), disc bulging, disc herniation, and disc herniation, as well as a delivery method and recommended treatment regimen for delivering an effective dose of the composition to a patient. The composition has the characteristics of inflammation resistance, oxidation resistance, vasodilation and spasmolysis. The composition is administered by intravenous drip over a specific period of time to relieve pain.

Provided is a use of the prophylaxis, amelioration or therapy of intractable epilepsy, for example, Focal Cortical Dysplasia (FCD).

The present invention relates to methods for treating patients with refractory chronic cough (RCC) with nalbuphine compositions, wherein the method provides a therapeutic effect in a patient.